Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

813.38 -19.06 (-2.29%)
Streaming Delayed Price Updated: 12:53 PM EST, Nov 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,487,735
Open 830.20
Bid (Size) 813.13 (8)
Ask (Size) 813.64 (11)
Prev. Close 832.44
Today's Range 812.12 - 833.99
52wk Range 561.65 - 972.53
Shares Outstanding N/A
Dividend Yield 0.56%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, predicting significant stock outperformance. 
Via Benzinga
Biotech Stocks Are Rallying: What Is Your Playbook?
If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers. 
Via Talk Markets

Performance

YTD
+37.35%
+37.35%
1 Month
-12.49%
-12.49%
3 Month
-8.03%
-8.03%
6 Month
+7.35%
+7.35%
1 Year
+32.75%
+32.75%

More News

Read More
Tesla Remains Core For Gary Black Despite Price Cuts, Earnings Drop — Nvidia, Google, Eli Lilly Among Top Performers In Tech Bull's Portfolio
Via Benzinga
Topics Electric Vehicles
Exposures Electric Vehicles
1 Stubborn Cloud and 2 Silver Linings for Eli Lilly Stock
Via The Motley Fool
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
Assessing Eli Lilly's Performance Against Competitors In Pharmaceuticals Industry
Via Benzinga
Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?
Via The Motley Fool
Is Viking Therapeutics a Buy on the Dip?
Via The Motley Fool
MarketBeat Week in Review – 11/4 - 11/8
Via MarketBeat
Topics Economy Government
Exposures Interest Rates Political
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Via Benzinga
Investors Like Certainty. Trump's Win Gave Them Some.
Via The Motley Fool
Topics Government
Exposures Political
How Altimmune Could Grab a Big Chunk of the GLP-1 Market
Via MarketBeat
Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock.
Via The Motley Fool
Smaller Cap Biotechs Are In Season: How Are We Doing?
Via Talk Markets
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Via Benzinga
Topics Death
Exposures Death Product Safety
Eli Lilly Posts a Huge Earnings Miss. Should Investors Be Worried?
Via The Motley Fool
Topics Earnings
Exposures Financial
Missed Out on Eli Lilly? Buy This Amazing Growth Stock Instead
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Is Eli Lilly a Buy? Analyst Confidence Grows for 2025
Via MarketBeat
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
Via Talk Markets
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Via Benzinga
What's Going On With Hims & Hers Health Stock Monday?
Via Benzinga
As Race To Best 'Miracle' Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%
Via Benzinga
Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data
Via Investor's Business Daily
Could This Near Trillion-Dollar Stock Be a Millionaire Maker?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.